Continued investment from big pharma and a slew of new drugs with novel mechanisms of action are fueling investor interest in the antiviral space.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anonymous. The World Market for Anti-Infectives, Volume III. Antiviral Drugs (Kalorama Information, Rockville, MD, USA, 2007).
Anonymous. The Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape (Arrowhead Publishers, Minneapolis, MN, USA, 2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author is an employee of Novartis Vaccines
Rights and permissions
About this article
Cite this article
McCarthy, B. Antivirals—an increasingly healthy investment. Nat Biotechnol 25, 1390–1393 (2007). https://doi.org/10.1038/nbt1207-1390
Issue Date:
DOI: https://doi.org/10.1038/nbt1207-1390
This article is cited by
-
Comparative Study of Electrospun Scaffolds Containing Native GAGs and a GAG Mimetic for Human Mesenchymal Stem Cell Chondrogenesis
Annals of Biomedical Engineering (2020)